Last reviewed · How we verify
T3011 high dose
At a glance
| Generic name | T3011 high dose |
|---|---|
| Sponsor | Shanghai Pharmaceuticals Holding Co., Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC (PHASE2)
- A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors (PHASE1, PHASE2)
- Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |